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ABSTRACT
Objectives: In addition to the rise in obesity prevalence globally, morbidity due to nonalcoholic fatty liver disease is increasing. Primary modalities for 
preventing and managing this problem include dietary modification and improved physical activities. A daily diet with a low n-6:n-3 polyunsaturated 
fatty acid (PUFA) ratio is suspected to contribute to ameliorating liver steatosis (LS). The present study was conducted to elucidate the effects of an 
n-6:n-3 PUFA ratio of 2:1 in alleviating LS.
Methods: Twenty-four young obese women with LS were recruited from Denpasar, Bali, Indonesia. They were randomly allocated to an intervention 
or control group. Both groups were given linoleic acid:α-linolenic acid at ratios of 2035:970 and 240:100 g, respectively, for 12 weeks. Baseline and 
end-line data were obtained. All patients were advised to maintain their daily energy intake no more than 1500 kcal and to perform structured 
physical exercises once a week.
Results: The intervention significantly decreased the body fat (body mass index, p=0.040; triglyceride, p=0.008) and serum tumor necrosis factor-α 
(TNF-α) levels (p=0.002) and increased serum interleukin-10 (IL-10) levels (p=0.004). The severity of LS was reduced through the intervention (odds 
ratio=0.064; 95% confidence interval=0.013-0.310; p=0.001).
Conclusion: An increased intake of 2:1 n-6:n-3 PUFA ratio alleviated LS, decreased body fat composition and serum TNF-α levels, and increased 
serum IL-10 levels.
Keywords: Young obese women, 2:1 n-6:n-3 Polyunsaturated fatty acid ratio, Cytokines, Liver steatosis.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD), or liver steatosis (LS), is an 
emerging global health problem. It has been associated with an increase 
in morbidity in western populations and is currently also affecting 
Southeast Asian populations. NAFLD is an accumulation of fat in the 
liver of nonalcoholic individuals. This accumulation of fat, particularly 
intrahepatic triglycerides (TGs), occurs due to several mechanisms, 
i.e, increased influx of free fatty acids into the liver, increased fat 
synthesis, decreased TG export through very low-density lipoprotein 
(VLDL), and reduced β-oxidation [1-3]. Fat accumulation indicates 
that hepatic fatty acid uptake from the plasma and de novo fatty acid 
synthesis occur at a faster rate than do β-oxidation and export [3]. 
NAFLD occurs as two entities, i.e, non-alcoholic fatty liver (NAFL) and 
succeeded by non-alcoholic steatohepatitis (NASH) in the later stage. 
NAFL is defined as hepatic steatosis without inflammation, whereas 
NASH is steatosis accompanied by inflammation [3]. NAFLD is the most 
common liver disorder and is the leading cause of hepatocyte injury 
and fibrosis. NAFLD is also associated with chronic liver diseases such 
as cirrhosis [4-8].
The two-hit theory explains the development and progression of NAFLD. 
The first hit initiates LS, and the second hit stimulates inflammatory 
processes. These two conditions may result in hepatocyte injury and 
fibrosis [4,5]. NAFLD is asymptomatic, undetectable, and progressive. 
Except for individuals who consume more than 20 g of ethanol daily, 
imaging studies or liver biopsies can be used to diagnose NAFLD. 
Liver biopsy is the definitive method for diagnosing NAFLD, yet this 
method is invasive, traumatic, and expensive. Ultrasound (US) imaging 
is an alternative method for diagnosing suspected NAFLD cases. This 
method is relatively safe and inexpensive, with good sensitivity and 
specificity [9].
Approximately 20-35% of the global population has LS, and 10% of 
cases are more severe than NASH. The prevalence of LS is higher among 
patients with obesity and type 2 diabetes (70-80%), and as many as 25-
70% of these patients eventually develop chronic liver diseases such as 
NASH and fibrosis [6-8]. Obesity, a high-fat diet, a genetic predisposition, 
and microbiota have been identified as risk factors for NAFL [4-8]. In 
obese patients associated chronic inflammatory states, the adipose tissue 
releases more pro-inflammatory cytokines such as tumor necrosis factor-α 
(TNF-α) and interleukin (IL)-6, whereas the release of IL-10 is decreased. 
Moreover, the levels of pro-inflammatory cytokines, such as TNF-α and 
IL-16, produced by the liver and adipose tissue are elevated during the 
activation of nuclear factor kappa B. TNF-α involves in inflammatory and 
metabolic alterations nearly stage of liver injury, leading to increased 
cytokines synthesis, which in turn induces cell migration, initiate fibrotic 
processes, and influence the progression of NAFL to NASH [4-8]. By 
contrast, IL-10 inhibits the synthesis of pro-inflammatory cytokines 
such as interferon-γ, IL-2, IL-3, and TNF-α. These cytokines are mainly 
secreted by T regulatory cells. Obesity is associated with decreased IL-
10 concentrations [10]. Research has shown that an imbalance between 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i12.20851
Research Article
75
Asian J Pharm Clin Res, Vol 10, Issue 12, 2017, 74-79
 Weta et al. 
pro-inflammatory (TNF-α) and anti-inflammatory (IL-10) cytokine 
levels are associated with a high n-6:n-3 ratio in the cell membranes of 
obese patients. The amounts of n-3 polyunsaturated fatty acid (PUFA) 
(α-linolenic acid [ALA]) and long-chain (LC)-PUFA (eicosapentaenoic acid 
[EPA] and docosahexaenoic acid [DHA]) in obese patients were shown to 
be, respectively, 30% and 35% lower than those in normal-weight patients. 
By contrast, n-6 PUFA (linoleic acid [LA]) and LC-PUFA (arachidonic acid 
[AA]) levels were shown to be relatively higher in obese patients than in 
non-obese patients [11]. Another study demonstrated that an increased 
n-6:n-3 PUFA ratio induces steatosis and inflammation, which leads to 
NAFLD [12]. Nutritional modification, such as increasing the n-3 PUFA 
proportion in the diet, can reduce the risk of obesity, inflammation, and 
oxidative stress and prevent the development of LS [13]. Few types of 
oil, such as canola oil, contain high n-3 PUFA (ALA) concentration. ALA 
is desaturated and elongated to EPA and DHA. n-3 LC-PUFA reduces 
lipogenic processes in the liver by inhibiting the sterol regulatory element 
binding protein-1c (SREBP1c) and carbohydrate-responsive element-
binding protein. Furthermore, it also stimulates paroxysmal proliferator-
activated receptor (PPAR)-α and activates a protein kinase (AMPK) to 
increase the β-oxidation of hepatic lipids. It also increases lipid oxidation 
in adipose and skeletal tissues through AMPK [14]. The present study was 
conducted to elucidate the effects of n-6:n3 PUFA supplementation at a 
ratio of 2:1 for alleviating LS and improving serum TNF-α and IL-10 levels 
in young Balinese obese women.
METHODS
Research design, participants, and intervention
This study was a randomized trial with a double-blind control group-
based pre- and post-test design [15]. It involved young obese women 
(age, 18-25 years) in Denpasar. They were recruited between May and 
September 2013 (clinical trial ID ACTRN12615000757516).
This study is part of a larger research project investigating the effects 
of low-ratio n-6:n-3 PUFA supplementation for alleviating obesity and 
its comorbidities in young obese women in Bali. Sixty-six young obese 
women (body mass index [BMI] ≥25 kg/m2) were screened for LS 
through US imaging (Logiq 500, GE, Solingen, Germany); 26 (39.4%) of 
them were found to have LS and were randomly enrolled in this study. 
They were allocated to either intervention or control group (13 patients 
in each group). Informed consent was obtained from all patients before 
enrolment. The study protocol was approved by the Research Ethics 
Committee of Udayana University, Sanglah Hospital (Ethical Clearance 
No. 787/UN.14.2/Litbang/2012, 17 September 2012).
The intervention group received supplementation with 30 mL of 
emulsion containing 10 g of canola oil (952 mg of saturated fatty acid 
[SFA], 6072 mg of monounsaturated fatty acid [MUFA], 2035 mg of LA, 
and 970 mg of ALA; n-6:n-3 PUFA ratio of 2:1) [16,17], and the control 
group received supplementation with 30 mL of placebo containing 2 g 
of palm oil (660 mg of SFA, 1000 mg of MUFA, 240 mg of LA, and 100 
mg of ALA; n-6:n-3 PUFA ratio of 2:1) [17,18]. Supplementation was 
provided daily for 12 weeks (June 2013-September 2013). Furthermore, 
the participants were advised to restrict their daily energy intake to 
<1500 kcal. To ensure compliance, weekly meetings (every Sunday) were 
organized. During these meetings, they were advised to participate in 
aerobic exercises for 1 hr under the supervision of a gym instructor. They 
were given 250 mL of emulsions per week, and any complaints or adverse 
effects related to the supplementation were monitored. To ensure that, 
the previous week’s dose was consumed as instructed, and the volume of 
the remaining emulsion in the used bottles was recorded.
During this period, two participants from the intervention group were 
lost to follow-up. In total, 24 patients (11 in the intervention group 
and 13 in the control group) completed the study protocol and were 
included in the analysis.
Data collection
All research variables were assessed on the first day of week 1 
(baseline data) and last day of week 12 (end-line data). Energy intake 
was assessed using a semi-quantitative food frequency questionnaire. 
Body weight (BW) was measured using a digital scale (Omron HBF-362 
model, Kyoto, Japan), with a precision of 0.1 kg, and body height (BH) 
was measured using a stature meter, with an accuracy of 0.1 cm. BMI 
was calculated as BW (kg)/BH (m)2. Serum TG and gamma glutamyl 
transferase (GGT) levels were measured using the colorimetric method 
(Cobas 6000-Roche Diagnostic, Mannheim, Germany), with precisions 
of 1 mg/dL and 1 μg/L, respectively.
Serum TNF-α and IL-10 levels were assessed using an ELISA kit (Boster 
Biological Technology Ltd, Pleasanton, CA, USA), according to the 
manufacturer’s instructions. The results were examined with an ELISA 
reader (pg/mL).
LS was assessed through US imaging, the results of which were 
independently interpreted by three radiologists. The final 
interpretation was determined through majority decision. The defining 
criteria for LS are as follows: (1) Normal liver (absence of steatosis 
and other liver disorders), (2) mild steatosis (appearance of a slightly 
bright liver parenchymal or hepatorenal echo contrast without 
intrahepatic vascular disorder), (3) moderate steatosis (more colored 
liver parenchymal or hepatorenal appearance in more areas without 
intrahepatic vascular disease), and (4) severe steatosis (diffused 
and brighter liver appearance with blunting intrahepatic vascular 
disorder) [19,20].
Statistical analyses
Statistical analyses were performed using Stata 12.1 (Stata Corp, College 
Station, TX, USA). A generalized linear model was employed to explore 
the relationships of variables within and between the groups. Repeated 
ordered logistic regression was used to assess the ORs between severe 
and less severe LS. The significance level for all statistical analyses was 
p<0.05 (95% confidence intervals [CI]) [21] (Fig. 1).
RESULTS
All participants were Balinese, with the mean age of 20.8±1.7 years 
(range, 18-24 years). Most participants were students of Udayana 
University (87.5%). All of the baseline characteristics, namely, age, 
occupation, selected nutrients intake (except cholesterol), BMI, 
waist circumference, TG, and GGT were comparable between the 
intervention and the control group. However, two nutrient intakes, 
namely, cholesterol and fiber were in extreme values. There was a 
high cholesterol intake in the intervention group (354 mg) compared 
to the control group (240 mg) (p=0.033). In contrary for the fiber 
consumption, both the intervention and the control group had a 
low-fiber intake (7.86 g and 12.8 g; p=0.135 respectively), less than 
Indonesian RDA (32 g) (Table 1). The sources of fat intake were mainly 
palm oil, chicken, and red meat (Table 2).
The reduced total energy intake between the baseline and end-line did 
not differ in the intervention and control groups (p=0.053 and p=0.551, 
respectively) and remained at >1500 kcal in both the groups. Moreover, 
no significant difference was observed in the changes in total energy 
intake between the two groups (p=0.257; Table 3).
In the intervention group, a significant reduction in the BMI and TG 
levels between the baseline and end-line was noted (p=0.040 and 
p=0.008, respectively), but this finding was not observed in the control 
group. The BMI and TG levels did not differ between the two groups 
(BMI, p=0.150; TG, p=0.433). A greater reduction in serum GGT levels 
occurred in the intervention group than in the control group, but this 
difference was not statistically significant.
Serum TNF-α and IL-10 concentrations were not normally distributed; 
therefore, log transformation was performed. In the intervention group, 
the concentration of serum TNF-α decreased from baseline and end-
line (p=0.002), whereas the IL-10 concentration increased (p=0.004). 
By contrast, only the IL-10 serum concentration increased (p=0.0038; 
Table 3) in the control group.
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Table 1: Baseline characteristics of participants stratified by 
group





Age (years) 21.2±1.8 20.5±1.7 0.338
Occupation
F (%)
Student 10 (90.9) 11 (84.6) 0.589
Officer staff 1 (9.1) 1 (7.7)
Unemployment - 1 (7.7)
Specified nutrients intake
Energy (kcal) 2187±203 1714±170 0.848
Fat (g) 82.0±9.11 67.9±13.5 0.976
PUFA (g) 19.1±3.09 15.8±3.36 0.978
Cholesterol (mg) 354±48.1 240±40.3 0.033
Fiber (g) 7.86±0.91 12.8±3.36 0.135
BMI (kg/m2) 33.8±2.32 34.1±1.33 0.916
Triglyceride (mg/dl) 157±16.5 130±22.5 0.580
GGT (μg/l) 25.8±2.94 25.2±2.88 0.351
PUFA: Polyunsaturated fatty acids, BMI: Body mass index, GGT: Gamma 
glutamyl transferase, SE: Standard error
Fig. 1: Sequence of participants recruitment and pathways of research procedure
Compared with the control group, a significant improvement was 
noted in the LS condition of the intervention group after the 12-week 
intervention, with an OR of 0.064 (95% CI 0.013–0.310, p=0.001; 
Table 3).
DISCUSSION
Following the present findings, most studies - both in animals and 
humans -have documented the benefits of n-3 PUFA supplementation 
for treating NAFLD by improving the cytokine profiles and reducing 
inflammation and oxidative stress.
In a recent animal model study, Konuma et al. used plant oils as a source 
of n-3 PUFA demonstrated that a low n-6:n-3 PUFA ratio improved 
serum lipid metabolism, inflammatory cytokines levels, oxidative 
stress, and endothelial function. They found that EPA effectively 
prevented the development and progression of NASH and ameliorated 
hepatic steatosis in mice [22]. Heerwagen et al. revealed that a high-
fat diet significantly increased the n-3:n-6 PUFA ratio and reduced 
maternal obesity-associated inflammation in Fat-1 transgenic mice. 
In that study, wild-type mice fed with a high-fat diet exhibited a high 
serum concentration of 12 pro-inflammatory cytokines (p<0.05), but 
no such increase was observed in the transgenic mice [23]. Depner 
et al. reported that among n-3 LC-PUFAs, DHA was more effective than 
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EPA in attenuating inflammation, oxidative stress, fibrosis, and hepatic 
damage [24]. Lionetti et al. described that EPA effectively minimized 
saturated fat-induced insulin resistance in mice and decreased leptin 
alleviated LS and improved secondary outcomes, such as BMI, TG and 
alanine transaminase levels, and homeostasis model assessment of 
insulin resistance values in both groups when compared to the control 
group [25]. A systematic review and meta-analysis of five randomized 
controlled trials (nine studies) in which n-3 LC-PUFA supplementation 
was provided for 8 weeks to 12 months to 355 adults with NAFLD 
demonstrated that n-3 LC-PUFA was beneficial in reducing liver fat 
(p<0.001) and aspartate aminotransferase (p=0.02) but not alanine 
aminotransferase activity [26]. Another study reported that a reduction 
in the n-6:n-3 PUFA ratio (3:1) in the diet resulted in decreased plasma 
TG levels in mRNA expression in vivo and in vitro. A decline in the 
circulating levels of leptin may reduce the white adipose tissue mass 
and eventually reduce the BW and degree of systemic inflammation 
in rats. In another study [27], marine n-3 PUFAs were found to have 
an anti adipogenic effect during obesity development in mice. The 
study showed that it inhibited the growth of fat cells through both 
hypertrophy and hyperplasia processes. In human studies, Nobili et al. 
have demonstrated that supplementation with two doses of 250 mg 
and 500 mg of DHA daily for 2 years in children with NAFLD patients 
aged 45-75 years [28-30].
In the present study, the use of plant (canola) oil with an n-6 (LA):n-3 
(ALA) PUFA ratio of 2:1 appeared to improve the composition of 
n-6 (AA) and n-3 (EPA and DHA) LC-PUFAs in the phospholipid cell 
membrane. ALA desaturated and elongated in animal and human 
bodies to form LC PUFAs (EPA, DPA, and DHA). By contrast, LA 
desaturated and elongated to form γ-linolenic acid and dihomo-γ–
linolenic acid (DGLA), and DGLA desaturated to form n-6 LC-PUFA 
(AA) [31]. DGLA is a n-6 PUFA that produces anti-inflammatory 
eicosanoids, the prostaglandin 1 series (PG-1), which differ from 
the pro-inflammatory prostaglandin 2 series (PG-2) released by 
AA. In addition, ALA also desaturated and elongated to form EPA. 
Increased EPA levels potentially inhibit the δ-5 desaturase enzyme, 
which is required by DGLA to form AA [32]. Thus, this plant oil exerts 
its beneficial effects by increasing EPA levels and DLGA to produce 
PG-3 and PG-1 while inhibiting the AA formation that releases PG-2. 
Furthermore, a low n-6:n-3 PUFA ratio controls the inflammatory 
state by inducing the release of anti-inflammatory cytokines and 
inhibiting the release of pro-inflammatory cytokines.
In addition, Burdge et al. analyzed the EPA and DHA obtained from the 
desaturation and elongation of ALA. They observed that on average, as 
much as 36% of ALA was converted to n-3 LC-PUFA (21% EPA, 6% DPA, 
and 9% DHA) in young obese women. ALA conversion to n-3 LC-PUFA 
Table 3: Relationship of intervention with energy intake, body lipid composition, cytokine levels, and liver steatosis (n=24)
Parameter group Mean±SE p
Baseline Endline Difference
Energy intake (kcal)
Intervention (n=11) 2187±203 1691±209 −497±226 0.053
Control (n=13) 1714±170 1574±158 −140±206 0.511
p 0.257
BMI (kg/m2)
Intervention (n=11) 33.8±2.32 33.0±2.31 −0.74±0.31 0.040
Control (n=13) 34.1±1.33 34.5±1.11 0.43±0.69 0.546
p 0.150
Triglyceride (mg/dl)
Intervention (n=11) 157.4±16.5 129.1±16.2 −28.3±8.5 0.008
Control (n=13) 129.9±22.5 117.9±11.5 −11.9±17.3 0.505
p 0.433
GGT (μg/l)
Intervention (n=11) 25.8±2.94 21.8±2.74 −3.97±2.15 0.074
Control (n=13) 25.2±2.88 24.7±3.24 −0.45±1.67 0.788
p 0.202
Log. IL10
Intervention (n=11) 0.82±0.24 1.55±0.07 0.73±0.23 0.004
Control (n=13) 1.31±0.11 1.54±0.05 0.23±0.10 0.038
p 0.053
Log. TNF-α
Intervention (n=11) 1.87±0.06 1.58±0.08 −0.29±0.08 0.002
Control (n=13) 1.89±0.08 1.71±0.13 −0.18±0.15 0.242
p 0.516
Liver steatosis (0/1/2/3)†
Intervention (n=11) 0/5/3/3 5/3/2/1 5/−2/−1/−2 0.064
Control (n=13) 0/6/1/6 3/4/3/3 3/−2/2/−3 (0.013-0.31)††
p 0.001
SE: Standard error of the mean, TNF: Tumor necrosis factor, IL: Interleukin, GGT: Gamma glutamyl transferase. p, analyzed using a general linear model. †Liver steatosis 
level: 0, none; 1, mild; 2, moderate; 3, severe. The data are presented as the frequency distribution and analyzed using the ordinal generalized model.  ††OR (95% CI); OR 
of more severe to less severe liver steatosis
Table 2: Baseline fatty food consumption patterns (time/day) of 
the participants (n=24)
Fat sources F (%) Mean±SE
Animal
Beef 12 (50.0) 0.25±0.09
Pork 16 (66.7) 0.19±0.08
Lamb 8 (33.4) 0.27±0.09
Chicken 22 (91.7) 1.20±0.19
Full cream milk 10 (41.7) 0.25±0.72
Cheese 14 (58.3) 0.27±0.08
Butter/margarine 9 (37.5) 0.18±0.09
Fast food/street food
Fried chicken 19 (79.2) 0.45±0.35
Meatball (bakso) 19 (79.2) 0.21±0.07
Plant
Coconut oil 4 (16.7) 0.26±0.12
Palm oil 19 (79.2) 2.07±0.29
Olive oil 3 (12.5) 1.35±0.86
Fried food (camilan) 14 (58.3) 0.79±0.18
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was also reported to be higher among young obese women than among 
young obese men, probably due to the lower level of lipid β-oxidation 
among women [33].
EPA and DHA regulate adiposity through two mechanisms. First, 
n-3 LC-PUFAs reduce endogenous lipid production by inhibiting the 
expression and processing of SREBP1c, which stimulates lipogenic 
gene transcriptions [14,34,35]. Second, n-3 LC-PUFAs are potent 
PPAR-α activators and PPAR-γ inhibitors that upregulate several 
gene expression pathways involved in the stimulation of fatty acid 
β-oxidation [14,35-38].
In the present study, reduced TNF-α and increased IL-10 levels were 
associated with reduced inflammation in the participants after the 12-
week intervention. The release of GGT typically increases oxidative 
stress [39]; however, serum GGT levels were relatively decreased in this 
study, indicating that oxidative stress was reduced. Furthermore, GGT 
has been strongly associated with body lipids, particularly visceral fat, 
which contribute to the progression of NAFLD [23,24,40].
In animals study, other antioxidant nutrients also reported have a 
positive effect in reducing liver inflammatory and fibrosis. Abdel-
Sttar et al. [41] studied that hesperidin (3,5,7-trihydroxy flavanone-
7-rhamnoglucoside) and a flavanone glycoside present abundantly 
in citrus fruits, significantly ameliorated carbon tetrachloride (liver 
fibrosis inducer) in rats based on its antioxidant, anti-inflammatory, 
antilipidemic, and anti-fibrotic activities. Ahmed et al. [42] reported 
grape seeds (Vitis vinifera) extract contains flavonoids, polyphenols, 
anthocyanins, proanthocyanidins, procyanidins, and the stilbene 
derivative resveratrol bioactive phytochemicals that possess inhibitory 
activity on the fat-metabolizing enzymes, pancreatic lipase, and 
lipoprotein lipase. Vitis Vinifera seed extract has potent therapeutic 
implication in NASH accompanied with insulin resistance and severe 
inflammation. Human trials are clearly needed in the future in 
order to confirm whether or not the combination of those nutrients 
supplementation with n-6:n-3 PUFA on 2:1 ratio can strengthen the 
effects of the present study. 
Many risk factors, such as unhealthy diet comprising high energy, high 
saturated fat, and high n-6:n3 PUFA ratio, along with sedentary lifestyle, 
are associated with obesity and insulin resistance. It facilitates the 
influx of free fatty acids from the adipose tissue into the liver, hepatic 
oxidative stress, cytokine production, reduced VLDL secretion, and 
the growth of the intestinal microbiome [43]. Unhealthy diet and a 
sedentary lifestyle can alter the stability of the intestinal microbiome 
composition. This leads to the development of chronic diseases such 
as obesity and metabolic dysfunction [44]. These factors are associated 
with the progression of NAFL to NASH.
NAFLD is asymptomatic and undetectable in its early stages, and a 
definitive pharmacologic regimen has yet to be identified. If NAFLD is 
neither identified in its early stages nor managed appropriately, the 
disease will naturally progress to the severe NASH stage, which entails 
inflammation, fibrosis, and cirrhosis [3]. Non-invasive US imaging is an 
appropriate first-line method for the early detection of asymptomatic 
NAFLD [40]. Schwenger et al. [3] recommended that an improvement in 
diet and increase in physical activity should be the first choice to treat 
NAFLD, followed by the management of insulin resistance, oxidative 
stress, and obesity-associated morbidity.
The results of this study suggest that the risk of NAFLD should be 
monitored among obese patients. Early identification and appropriate 
management of LS are crucial, particularly among obese patients. An 
improvement in the quality of life through the modification of daily 
life behaviors, such as by maintaining a healthy and balanced diet and 
increasing physical activities, is essential to effectively manage LS. 
Healthy diets and supplementation with a low n-6:n-3 PUFA ratio are 
beneficial in alleviating and treating NAFLD, improving the body lipid 
composition, and controlling inflammation.
We conclude that daily supplementation with an n-6:n-3 PUFA ratio 
of 2035:970 mg (LA:ALA) for 12 weeks alleviates LS reduces body 
fat composition and serum TNF-α levels and increases the serum 
concentration of IL-10 in young obese Balinese women.
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